BioPharma Dive September 8, 2025
The companies said their updated shot spurred a notable increase in neutralizing antibodies against a currently circulating strain, answering calls for more corroborating evidence.
Dive Brief:
- Pfizer and partner BioNTech said Monday their updated COVID-19 booster spurred strong immune responses against currently circulating coronavirus strains in late-stage testing, adding a key piece of evidence in support of the recently approved shot.
- According to Pfizer and BioNTech, the booster led to at least a four-fold increase in levels of LP.8.1-neutralizing antibody titers in a study cohort of people either over 65 or who are between 18 and 64 and have an underlying health condition. No new safety concerns were identified.
- The two companies ran the study to provide to the...
Today's Sponsors
Today's Sponsor